BioCentury
ARTICLE | Clinical News

Trabodenoson: Phase III start

November 16, 2015 8:00 AM UTC

Inotek began the double-blind, U.S. Phase III MATRx-1 trial to compare topical trabodenoson vs. twice-daily placebo or 0.5% timolol for 12 weeks in both eyes in about 335 patients with an IOP of 24-34...